{"pmid":32439198,"title":"Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More.","text":["Probable Molecular Mechanism of Remdesivir for the Treatment of COVID-19: Need to Know More.","COVID-19 is now pandemic throughout the world. Scientist, doctors are searching for effective therapy of this diseases. The remdesivir, an antiviral drug, is appeared as 'molecule of hope' for the treatment of this disease. USFDA approve this drug for the treatment of COVID-19. The molecular mechanism is unknown. In this paper, we tried to describe the probable molecular mechanism of remdesivir to inhibit the RNA synthesis of SARS-CoV-2. However, more detail mechanism is needed to understand mechanism of action of remdesivir.","Arch Med Res","Saha, Abinit","Sharma, Ashish Ranjan","Bhattacharya, Manojit","Sharma, Garima","Lee, Sang-Soo","Chakraborty, Chiranjib","32439198"],"abstract":["COVID-19 is now pandemic throughout the world. Scientist, doctors are searching for effective therapy of this diseases. The remdesivir, an antiviral drug, is appeared as 'molecule of hope' for the treatment of this disease. USFDA approve this drug for the treatment of COVID-19. The molecular mechanism is unknown. In this paper, we tried to describe the probable molecular mechanism of remdesivir to inhibit the RNA synthesis of SARS-CoV-2. However, more detail mechanism is needed to understand mechanism of action of remdesivir."],"journal":"Arch Med Res","authors":["Saha, Abinit","Sharma, Ashish Ranjan","Bhattacharya, Manojit","Sharma, Garima","Lee, Sang-Soo","Chakraborty, Chiranjib"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32439198","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.arcmed.2020.05.001","keywords":["covid-19","remdesivir","sars-cov-2","therapeutic molecule"],"e_drugs":["remdesivir"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667535119434383360,"score":9.490897,"similar":[{"pmid":32389723,"title":"Computational screening of antagonist against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking.","text":["Computational screening of antagonist against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking.","In the current episode of novel coronavirus (SARS-CoV-2) spreads, antiviral drug discovery is of great importance. Auto dock vina was used to screen potential drugs by molecular docking with the structure protein and non-structure protein sites of new coronavirus. Ribavirin, a common antiviral drug, as well as remdesivir, chloroquine and luteolin, were all studied. Honeysuckle is generally believed to have antiviral effect in traditional Chinese medicine, the main flavonoid in which is Luteolin. In the study, it was found luteolin could bind to the same sites of main protease of SARS-CoV-2 as the control molecular with a high affinity. Chloroquine, was proved clinically effective, can bind to the main protease, which may be the possible antiviral mechanism. And the study was restricted to molecular docking without validation by MD simulations. Interactions with the main protease may play a key role in in fighting against viruses. Luteolin is a potential antiviral molecule worthy of attention.","Int J Antimicrob Agents","Yu, Ran","Chen, Liang","Lan, Rong","Shen, Rong","Li, Peng","32389723"],"abstract":["In the current episode of novel coronavirus (SARS-CoV-2) spreads, antiviral drug discovery is of great importance. Auto dock vina was used to screen potential drugs by molecular docking with the structure protein and non-structure protein sites of new coronavirus. Ribavirin, a common antiviral drug, as well as remdesivir, chloroquine and luteolin, were all studied. Honeysuckle is generally believed to have antiviral effect in traditional Chinese medicine, the main flavonoid in which is Luteolin. In the study, it was found luteolin could bind to the same sites of main protease of SARS-CoV-2 as the control molecular with a high affinity. Chloroquine, was proved clinically effective, can bind to the main protease, which may be the possible antiviral mechanism. And the study was restricted to molecular docking without validation by MD simulations. Interactions with the main protease may play a key role in in fighting against viruses. Luteolin is a potential antiviral molecule worthy of attention."],"journal":"Int J Antimicrob Agents","authors":["Yu, Ran","Chen, Liang","Lan, Rong","Shen, Rong","Li, Peng"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32389723","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.ijantimicag.2020.106012","keywords":["2019-ncov","autodock vina","chloroquine","luteolin","remdesivir","ribavirin"],"locations":["vina","Chinese","flavonoid"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Chloroquine","Luteolin","Flavonoids","Ribavirin","remdesivir"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666528580014702592,"score":189.81728},{"pmid":32281114,"title":"Delayed Initiation of Remdesivir in a COVID-19 Positive Patient.","text":["Delayed Initiation of Remdesivir in a COVID-19 Positive Patient.","A case of late initiation of remdesivir antiviral therapy in the successful treatment of a patient with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a mixed medical ICU of a community teaching hospital is presented. A previously healthy 40 year-old male was admitted to the hospital three days after the onset of coronavirus disease 2019 (COVID-19) symptoms, including dry cough, fever, and shortness of breath progressing to intubation and increased mechanical ventilator support. A request for compassionate use remdesivir was submitted on the same hospital day as the positive COVID-19 PCR result. Supportive measures, in addition to a 5-day course of hydroxychloroquine, were maintained until remdesivir could be supplied on day 9 of hospitalization, 13 days after symptom onset. Sixty hours after initiating remdesivir, the patient was successfully extubated and was able to transition to room air within 24 hours of extubation. Late initiation of remdesivir may be effective in treating SARS-CoV-2, unlike antivirals utilized for different disease states, such as oseltamivir, which are most effective when started as soon as possible following symptom onset. Urgent action is needed by regulatory agencies to work with drug manufacturers to expedite the study and approval of investigational agents targeting SARS-CoV-2 as well as to meet manufacturing demands.","Pharmacotherapy","Hillaker, Emily","Belfer, Julie J","Bondici, Anamaria","Murad, Hani","Dumkow, Lisa E","32281114"],"abstract":["A case of late initiation of remdesivir antiviral therapy in the successful treatment of a patient with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a mixed medical ICU of a community teaching hospital is presented. A previously healthy 40 year-old male was admitted to the hospital three days after the onset of coronavirus disease 2019 (COVID-19) symptoms, including dry cough, fever, and shortness of breath progressing to intubation and increased mechanical ventilator support. A request for compassionate use remdesivir was submitted on the same hospital day as the positive COVID-19 PCR result. Supportive measures, in addition to a 5-day course of hydroxychloroquine, were maintained until remdesivir could be supplied on day 9 of hospitalization, 13 days after symptom onset. Sixty hours after initiating remdesivir, the patient was successfully extubated and was able to transition to room air within 24 hours of extubation. Late initiation of remdesivir may be effective in treating SARS-CoV-2, unlike antivirals utilized for different disease states, such as oseltamivir, which are most effective when started as soon as possible following symptom onset. Urgent action is needed by regulatory agencies to work with drug manufacturers to expedite the study and approval of investigational agents targeting SARS-CoV-2 as well as to meet manufacturing demands."],"journal":"Pharmacotherapy","authors":["Hillaker, Emily","Belfer, Julie J","Bondici, Anamaria","Murad, Hani","Dumkow, Lisa E"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32281114","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1002/phar.2403","keywords":["covid-19","sars-cov-2","coronavirus","pneumonia","remdesivir","viral pneumonia"],"e_drugs":["remdesivir","Oseltamivir","Hydroxychloroquine"],"topics":["Case Report"],"weight":1,"_version_":1666138491444002818,"score":178.40358},{"pmid":32446287,"title":"Remdesivir: Review of pharmacology, pre-clinical data and emerging clinical experience for COVID-19.","text":["Remdesivir: Review of pharmacology, pre-clinical data and emerging clinical experience for COVID-19.","The global pandemic of novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created an urgent need for effective antivirals. Remdesivir (formerly GS-5734) is a nucleoside analogue pro-drug currently being evaluated in COVID-19 clinical trials. Its unique structural features allow high concentrations of the active triphosphate metabolite to be delivered intracellularly and it evades proofreading to successfully inhibit viral RNA synthesis. In pre-clinical models, remdesivir has demonstrated potent antiviral activity against diverse human and zoonotic beta-coronaviruses, including SARS-CoV-2. In this article we critically review available data on remdesivir with an emphasis on biochemistry, pharmacology, pharmacokinetics and in vitro activity against coronaviruses as well as clinical experience and current progress in COVID-19 clinical trials.","Pharmacotherapy","Jorgensen, Sarah Cj","Kebriaei, Razieh","Dresser, Linda D","32446287"],"abstract":["The global pandemic of novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created an urgent need for effective antivirals. Remdesivir (formerly GS-5734) is a nucleoside analogue pro-drug currently being evaluated in COVID-19 clinical trials. Its unique structural features allow high concentrations of the active triphosphate metabolite to be delivered intracellularly and it evades proofreading to successfully inhibit viral RNA synthesis. In pre-clinical models, remdesivir has demonstrated potent antiviral activity against diverse human and zoonotic beta-coronaviruses, including SARS-CoV-2. In this article we critically review available data on remdesivir with an emphasis on biochemistry, pharmacology, pharmacokinetics and in vitro activity against coronaviruses as well as clinical experience and current progress in COVID-19 clinical trials."],"journal":"Pharmacotherapy","authors":["Jorgensen, Sarah Cj","Kebriaei, Razieh","Dresser, Linda D"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32446287","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/phar.2429","keywords":["covid-19","gs-5734","remdesivir","sars-cov-2","coronavirus","severe acute respiratory syndrome"],"topics":["Treatment"],"weight":1,"_version_":1667600475762982912,"score":176.8733},{"pmid":32428865,"title":"Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies.","text":["Remdesivir in COVID-19: A critical review of pharmacology, pre-clinical and clinical studies.","BACKGROUND & AIMS: Remdesivir is a broad spectrum anti-viral drug that has shown to inhibit SARS-CoV-2, in vitro and in vivo. In absence of any effective treatment for SARS-CoV-2 infection (COVID-19), remdesivir has been tried for a compassionate use in severe COVID-19. Newer randomized controlled studies that have recently become available, showed a mixed result. We aimed to systematically search the literature to understand the pharmacology and clinical effects of remdesivir in patients with COVID-19. METHODS: We systematically searched the PubMed, ClinicalTrial.Org and MedRxiv database up till May 5, 2020 using specific key words such as \"Remdesivir\" or 'GS-5734'' AND \"COVID-19\" or \"SARS-CoV-2\" and retrieved all the article published in English language, that have reported the pharmacology and the clinical outcomes of remdesivir in patients with COVID-19. RESULTS: Initial compassionate use of remdesivir has shown a fairly good result, but difficult to quantify, in the absence of control arm. While the very first double-blind, placebo-controlled, randomized trial conducted in Wuhan, did not find any significant benefit compared to the control, the preliminary result of another similar multi-country trial has shown a significant faster time to recovery but without any difference in mortality. CONCLUSIONS: Remdesivir has shown a mixed result in patients with COVID-19 with an acceptable side effect. However, jury is still out while awaiting the results from the forthcoming trials.","Diabetes Metab Syndr","Singh, Awadhesh Kumar","Singh, Akriti","Singh, Ritu","Misra, Anoop","32428865"],"abstract":["BACKGROUND & AIMS: Remdesivir is a broad spectrum anti-viral drug that has shown to inhibit SARS-CoV-2, in vitro and in vivo. In absence of any effective treatment for SARS-CoV-2 infection (COVID-19), remdesivir has been tried for a compassionate use in severe COVID-19. Newer randomized controlled studies that have recently become available, showed a mixed result. We aimed to systematically search the literature to understand the pharmacology and clinical effects of remdesivir in patients with COVID-19. METHODS: We systematically searched the PubMed, ClinicalTrial.Org and MedRxiv database up till May 5, 2020 using specific key words such as \"Remdesivir\" or 'GS-5734'' AND \"COVID-19\" or \"SARS-CoV-2\" and retrieved all the article published in English language, that have reported the pharmacology and the clinical outcomes of remdesivir in patients with COVID-19. RESULTS: Initial compassionate use of remdesivir has shown a fairly good result, but difficult to quantify, in the absence of control arm. While the very first double-blind, placebo-controlled, randomized trial conducted in Wuhan, did not find any significant benefit compared to the control, the preliminary result of another similar multi-country trial has shown a significant faster time to recovery but without any difference in mortality. CONCLUSIONS: Remdesivir has shown a mixed result in patients with COVID-19 with an acceptable side effect. However, jury is still out while awaiting the results from the forthcoming trials."],"journal":"Diabetes Metab Syndr","authors":["Singh, Awadhesh Kumar","Singh, Akriti","Singh, Ritu","Misra, Anoop"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32428865","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.dsx.2020.05.018","keywords":["covid-19","clinical outcome","mortality","remdesivir","sars-co-v-2"],"locations":["vivo","quantify","Wuhan"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["remdesivir"],"topics":["Treatment"],"weight":1,"_version_":1667352728673714176,"score":176.80501},{"pmid":32094225,"pmcid":"PMC7152756","title":"The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.","text":["The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus.","Antiviral drugs for managing infections with human coronaviruses are not yet approved, posing a serious challenge to current global efforts aimed at containing the outbreak of severe acute respiratory syndrome-coronavirus 2 (CoV-2). Remdesivir (RDV) is an investigational compound with a broad spectrum of antiviral activities against RNA viruses, including severe acute respiratory syndrome-CoV and Middle East respiratory syndrome (MERS-CoV). RDV is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). Here, we co-expressed the MERS-CoV nonstructural proteins nsp5, nsp7, nsp8, and nsp12 (RdRp) in insect cells as a part a polyprotein to study the mechanism of inhibition of MERS-CoV RdRp by RDV. We initially demonstrated that nsp8 and nsp12 form an active complex. The triphosphate form of the inhibitor (RDV-TP) competes with its natural counterpart ATP. Of note, the selectivity value for RDV-TP obtained here with a steady-state approach suggests that it is more efficiently incorporated than ATP and two other nucleotide analogs. Once incorporated at position i, the inhibitor caused RNA synthesis arrest at position i + 3. Hence, the likely mechanism of action is delayed RNA chain termination. The additional three nucleotides may protect the inhibitor from excision by the viral 3'-5' exonuclease activity. Together, these results help to explain the high potency of RDV against RNA viruses in cell-based assays.","J Biol Chem","Gordon, Calvin J","Tchesnokov, Egor P","Feng, Joy Y","Porter, Danielle P","Gotte, Matthias","32094225"],"abstract":["Antiviral drugs for managing infections with human coronaviruses are not yet approved, posing a serious challenge to current global efforts aimed at containing the outbreak of severe acute respiratory syndrome-coronavirus 2 (CoV-2). Remdesivir (RDV) is an investigational compound with a broad spectrum of antiviral activities against RNA viruses, including severe acute respiratory syndrome-CoV and Middle East respiratory syndrome (MERS-CoV). RDV is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). Here, we co-expressed the MERS-CoV nonstructural proteins nsp5, nsp7, nsp8, and nsp12 (RdRp) in insect cells as a part a polyprotein to study the mechanism of inhibition of MERS-CoV RdRp by RDV. We initially demonstrated that nsp8 and nsp12 form an active complex. The triphosphate form of the inhibitor (RDV-TP) competes with its natural counterpart ATP. Of note, the selectivity value for RDV-TP obtained here with a steady-state approach suggests that it is more efficiently incorporated than ATP and two other nucleotide analogs. Once incorporated at position i, the inhibitor caused RNA synthesis arrest at position i + 3. Hence, the likely mechanism of action is delayed RNA chain termination. The additional three nucleotides may protect the inhibitor from excision by the viral 3'-5' exonuclease activity. Together, these results help to explain the high potency of RDV against RNA viruses in cell-based assays."],"journal":"J Biol Chem","authors":["Gordon, Calvin J","Tchesnokov, Egor P","Feng, Joy Y","Porter, Danielle P","Gotte, Matthias"],"date":"2020-02-26T11:00:00Z","year":2020,"_id":"32094225","source":"PubMed","week":"20209|Feb 24 - Mar 01","doi":"10.1074/jbc.AC120.013056","keywords":["ebola virus (ebov)","middle east respiratory syndrome coronavirus (mers-cov)","rna chain termination","rna-dependent rna polymerase (rdrp)","sars-cov-2","antiviral drug","coronavirus","drug development","enzyme inhibitor","nucleoside/nucleotide analog","plus-stranded rna virus","positive-sense rna virus","remdesivir","viral polymerase","viral replicase"],"e_drugs":["remdesivir","triphosphoric acid","Adenosine Triphosphate"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138490805420032,"score":173.33914}]}